Abstract
Bispecific Vγ9Vδ2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have